U.S. Markets closed

Cyclo Therapeutics, Inc. (CYTH)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
7.00+0.25 (+3.70%)
At close: 4:00PM EDT

Cyclo Therapeutics, Inc.

6714 NW 16th Street
Suite B
Gainesville, FL 32653
United States
386 418 8060
http://www.cyclotherapeutics.com

Sector(s)Healthcare
IndustryDrug Manufacturers—Specialty & Generic
Full Time Employees8

Key Executives

NameTitlePayExercisedYear Born
Mr. N. Scott FineCEO & Director479.58kN/A1957
Dr. Jeffrey L. TateCOO & Director252.93kN/A1958
Dr. Sharon H. HrynkowChief Scientific Officer, Sr. VP of Medical Affairs & Member of Scientific Advisory Board337.08kN/A1960
Mr. Joshua M. FineCFO & Sec.N/AN/A1982
Mr. George L. FailsExec. VP and Operations Mang.N/AN/A1945
Mr. Michael Eric LisjakChief Regulatory Officer & Sr. VP of Bus. Devel.N/AN/A1973
Dr. Gerald F. CoxActing Chief Medical OfficerN/AN/A1959
Mr. Russ BeldenActing Chief Commercial OfficerN/AN/AN/A
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Cyclo Therapeutics, Inc., a clinical stage biotechnology company, develops cyclodextrin-based products for the treatment of various diseases. The company's lead drug candidate is Trappsol Cyclo, an orphan drug for the treatment of Niemann-Pick Type C disease. It also sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. The company was formerly known as CTD Holdings, Inc. and changed its name to Cyclo Therapeutics, Inc. in September 2019. Cyclo Therapeutics, Inc. was founded in 1990 and is based in Gainesville, Florida.

Corporate Governance

Cyclo Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.